All In Biotech

BLA 761429 · Bristol-Myers Squibb

Opdivo Qvantig

Nivolumab, Hyaluronidase-Nvhy · Injection

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Dec 27, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,779

188 Phase 3, 304 recruiting

FAERS reports

136

36 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OPDIVO QVANTIG · NIVOLUMAB 600MG; HYALURONIDASE-NVHY 10000 UNITS PER 5ML(120MG/2000UNITS PER ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nivolumab" as an intervention, any sponsor and status, largest first.

All 1,779 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use35
  • fatigue12
  • rash12
  • product storage error11
  • arthralgia10
  • death8
  • diarrhoea7
  • constipation6
  • decreased appetite6
  • product dose omission issue6
  • nausea5
  • product storage issue5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202543
202693

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,745 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.